Sage Journals: Discover world-class research

Abstract

Background and Aims:

Methods:

Patients with biliary tract cancer with hilar involvement undergoing major liver resection and extrahepatic bile duct resection between 2011 and 2021 at a single center were retrospectively analyzed. The primary postoperative outcome was overall survival. Secondary outcomes were recurrence-free survival and postoperative complications. Survival analysis was performed with Cox regression analysis and Kaplan–Meier method.

Results:

One-hundred and eight patients were included. Seventy-three (67%) had PHCC, 24 (22%) had GBC, and 11 (10%) had IHCC. Hilar-invading IHCC and GBC had more adverse histopathological factors like lymph node positivity (p = 0.021), higher number of positive nodes (p = 0.043), and larger tumor size (p < 0.001) compared with PHCC. Peritoneal invasion and lymph node positivity were significant independent predictors for survival (p = 0.011 and p = 0.004, respectively). Median overall survival was 29 months for PHCC, 22 months for GBC and 21 months for IHCC (p = 0.53). IHCC tended to recur earlier (p = 0.046) than GBC and PHCC (6, 15, and 18 months, respectively).

Conclusion:

Patients with biliary tract cancer with hilar involvement undergoing major liver resection and resection of extrahepatic bile ducts had similar overall survival regardless of subtype, while IHCC recurred earlier. Peritoneal cancer invasion was common in all subtypes, including PHCC, and was an independent prognostic factor. This finding may support routine reporting of peritoneal invasion-status in resected biliary tract cancer.

Keywords

Biliary tract cancer perihilar cholangiocarcinoma resection gallbladder cancer intrahepatic cholangiocarcinoma

Context and Relevance

For patients with biliary tract cancer involving the hepatic hilum, major hepatic resection with extrahepatic bile duct resection may be required. In addition to perihilar cholangiocarcinoma (PHCC), the same extent of surgery is used in advanced gallbladder cancer (GBC) and intrahepatic cholangiocarcinoma (IHCC) with hilar involvement. Few studies compare prognostic factors and long-term outcomes across tumor types. In this retrospective single-center study including 108 patients, we found a similar overall survival regardless of subtype, while IHCC recurred earlier. Peritoneal cancer invasion was common in all subtypes, including PHCC, and was an independent prognostic factor for survival. This finding may support routine reporting of peritoneal invasion-status in resected biliary tract cancer.

Introduction

Biliary cancer is a rare entity accounting for 1%–3% of all gastrointestinal malignancies with an incidence of 1–2 per 100,000/year.¹ Occurring in the biliary epithelium, it is subdivided into four groups; intrahepatic (IHCC), perihilar (PHCC), distal cholangiocarcinoma, and gallbladder cancer (GBC). Surgical resection is the only treatment offering a chance for long-term survival, but this option is open for just one-fourth of patients due to locally too advanced or metastatic disease at presentation.²

About 10% of GBC and IHCC are diagnosed at an advanced stage where the tumor infiltrates the hepatic hilum, with reported poor prognosis.^3,4 This often requires extended surgery with high postoperative morbidity and mortality questioning this aggressive surgical approach. Surgery involves major liver resection with extrahepatic bile duct resection, and in some cases, additional pancreaticoduodenectomy or portal vein resection and reconstruction to achieve tumor-negative margins.^5–7

With no reported difference in overall survival between the anatomical subtypes, most studies have reported separate histopathological results regarding biliary tract cancer but similar recommendations involving selection for surgery and/or oncological management.⁸ Two recent studies have compared the histopathological characteristics and outcome of different anatomical subtypes of biliary tract cancer, finding no significant differences in overall survival.^8,9 This questions prognosis, interpretation of oncological factors influencing survival and recurrence of biliary tract cancer subtypes. However, prognosis of biliary tract cancer with hilar engagement has only been investigated in one comparative and a few non-comparative studies, none of them including three anatomical subtypes.^3,4,10 These studies are also limited by a low number of patients or by their multi-center designs spanning over a long period of time where surgical approach and histopathological interpretation may differ widely.^4,3,10,11 Therein, the indications for this aggressive surgical approach and which patients may benefit from it remains an unsolved clinical dilemma.

Thus, this study aimed to investigate differences in prognostic factors and outcomes between patients with different biliary tract cancer subtypes engaging the hepatic hilum, treated by major liver resection including extrahepatic bile duct resection at a single high-volume center, to evaluate which patient-groups stand a greater chance to benefit from extensive surgery.

Methods

Patient selection and variables

All patients with histopathologically proven PHCC, IHCC, and GBC invading the hilum requiring major liver resection with extrahepatic bile duct resection, and if needed pancreaticoduodenectomy and/or portal vein resection, at Karolinska University Hospital (Stockholm, Sweden) between 2011 and 2021 were included. Major liver resection was defined as resection of ⩾3 liver segments. Also, complete hepatoduodenal ligament lymphadenectomy was done as well as sampling of the aortocaval (station 16b) and hepatic artery lymph nodes (8a), regardless of subtype. The retropancreatic lymph nodes (station 13) were sampled at the discretion of the operating surgeon. All data were obtained from medical records. Patients were subclassified and staged according to American Joint Committee on Cancer 8th edition staging system. Resection margins were categorized into margin to invasive cancer ⩾1 mm and margin to invasive cancer >0 mm. The margins reported were the transection margins of the distal bile duct, the proximal bile duct and the liver transection surface, and the circumferential dissection planes of the hepatoduodenal ligament and the hilum.¹² Additional factors analyzed for oncological outcomes included tumor size, grade of differentiation, lymph node positivity, number of positive lymph nodes, perineural invasion, and peritoneal perforation.

Postoperative complications were registered 90 days after surgery and classified according to the Clavien–Dindo (CD) system with major complications defined as CD IIIa–IV.¹² Postoperative mortality was regarded as death within 90 days after surgery (CD V). Overall survival was calculated from the date of resection to death from any cause or end of follow-up, including and excluding patients who died within 90 days of surgery. Recurrence-free survival was calculated from the date of resection to radiological evidence of local recurrence or distal metastasis with or without pathological confirmation.

Statistical analysis

Results were presented as numbers and percentages for categorical data and median with interquartile range (IQR) for continuous variables. Fisher’s exact test was used to compare categorical data and Kruskal–Wallis test was used for continuous data. The Kaplan–Meier method was used to estimate median overall and recurrence-free survival and to calculate survival curves.

Independent variables potentially affecting survival according to tumor and patient characteristics were analyzed using univariable and multivariable Cox proportional hazards regression models. A p value < 0.05 was regarded as statistically significant. Data were analyzed using SPSS 29.0 (IBM Corp., New York, US).

Ethical approval

Approval was obtained from the Regional Ethics Board in Stockholm, Sweden, Dnr 2022-06962-02, waiving the requirement of informed consent.

Results

Patient characteristics

A total of 108 patients with histologically proven biliary tract cancer undergoing major liver resection with extrahepatic bile duct resection were included in the study. The series included PHCC (n = 73), GBC (n = 24), and IHCC (n = 11). Median patient age was 64 years, and most patients were male (55%). No patient with distal cholangiocarcinoma had this operation during the study period. Patient characteristics are presented in Table 1.

Table 1.

Patient characteristics.

	PHCC (n = 73)	GBC (n = 24)	IHCC (n = 11)	P
Age (years)	63 (52–71)	65 (58–72)	73 (62–84)	0.169
Female gender	30 (41)	15 (62)	4 (36)	0.219
ASA 3	17 (23)	6 (25)	3 (27)	0.687
Body mass index (kg/m²)	24 (21–27)	25 (21–29)	24 (22–26)	0.702
Primary sclerosing cholangitis	9 (12)	1 (4)	2 (18)	0.574
Preoperative albumin (g/l)	32 (28–35)	33 (28–38)	34 (30–39)	0.482
Preoperative bilirubin (µmol/l)	15 (7–23)	14 (2–26)	8 (6–10)	0.007
Preoperative biliary decompression	56 (77)	18 (75)	4 (36)	0.032
Type of decompression				0.126
None	15 (21)	6 (25)	7 (64)
ERCP	37 (51)	13 (54)	2 (18)
PTBD	9 (12)		1 (9)
Both	11 (15)	5 (21)	1 (9)
Portal vein embolization	23 (32)	11 (46)	1 (9)	0.084
Preoperative future liver remnant <30%	12 (16)	11 (46)	1 (9)	0.015
Bismuth classification
1	2
2	2
3a	47
3b	17
4	7
Preoperative chemotherapy	3 (4)	1 (5)	1 (9)	0.799

PHCC: perihilar cholangiocarcinoma, GBC: gallbladder carcinoma, IHCC: intrahepatic cholangiocarcinoma, ASA: American Society of Anesthesiologists; ERCP:; PTBD.

Perioperative data

GBC patients underwent more extensive liver resections than the other groups, where almost 80% of patients were operated with an extended right hemihepatectomy. Postoperative mortality in the entire cohort was 13% with a significant difference between biliary tract cancer subtypes (p = 0.023) were the mortality risk in patients with GBC (29%) surpassed that of PHCC (10%) and IHCC (0 %). Perioperative data for the three groups are shown in Table 2.

Table 2.

Perioperative data.

	PHCC (n = 73)	GBC (n = 24)	IHCC (n = 11)	P
Type of liver resection				0.009
Right hemihepatectomy	8 (11)	5 (21)	0 (0)
Extended right hemihepatectomy	40 (55)	19 (79)	4 (36)
Left hemihepatectomy	14 (19)	0 (0)	6 (55)
Extended left hemihepatectomy	10 (14)	0 (0)	1 (9)
Concomitant resection of segment 1	60 (83)	9 (38)	5 (45)	<0.001
Additional pancreatoduodenectomy	4 (6)	3 (12)	0 (0)	0.500
Portal vein resection and reconstruction	19 (26)	5 (21)	1 (9)	0.568
Operative time (min)	357 (330–456)	351 (322–478)	337 (318–373)	0.537
Intraoperative blood loss (ml)	660 (440–1540)	500 (400–1000)	850 (675–2000)	0.299
Intraoperative blood transfusion	33 (46)	6 (25)	5 (45)	0.486
Major complication (Clavien–Dindo 3–4)	29 (40)	11 (44)	6 (55)	0.624
Death within 90 days	7 (10)	7^Δ (29)	0	0.023
Liver failure grade B or C	22 (30)	7 (29)	1 (9)	0.343
Bile leakage grade B or C	21 (29)	6 (25)	6 (55)	0.175
Re-laparotomy within 90 days	10 (13)	3 (12)	4 (36)	0.425
Need for interventional radiology	37 (51)	15 (62)	4 (36)	0.356
Main reason for intervention				0.164
Bleeding	6	2	0
Bile leakage	8	3	2
Abscess	14	3	0
Fluid collection	10	4	0
Other	1	3	2
Initial hospital length of stay (days)	12 (8-16)	9 (8-34)	14 (9-26)	0.619
Hospital readmission	31 (42)	5 (21)	6 (54)	0.087
Adjuvant chemotherapy	28 (38)	8 (33)	2 (18)	0.436

PHCC: perihilar cholangiocarcinoma, GBC: gallbladder carcinoma, IHCC: intrahepatic cholangiocarcinoma.

Including two patients who died of tumor dissemination within 3 months of operation.

Pathology characteristics

Tumor size was significantly larger (p < 0.001) in IHCC (90 mm) than in GBC (54 mm) and PHCC (30 mm), while lymph node positivity was most common (p = 0.021) in GBC (GBC 83%; IHCC 55%; PHCC 52%). Peritoneal cancer invasion occurred frequently in all groups: a majority of patients with GBC (61%), and approximately one third of patients with IHCC (36 %) and PHCC (33 %) (p = 0.061). Detailed pathology characteristics are presented in Table 3.

Table 3.

Pathology characteristics.

	PHCC (n = 73)	GBC (n = 24)	IHCC (n = 11)	P
Tumor size (mm)	30 (21–39)	54 (42–66)	90 (52–99)	<0.001
Lymph node positivity	38 (52)	20 (83)	6 (55)	0.021
Peritoneal invasion	23^€ (33)	14^& (61)	4 (36)	0.067
Lymphovascular invasion	57^# (88)	20^& (87)	11 (100)	0.704
Perineural invasion	59^*(98)	24 (100)	8^& (75)	0.063
Tumor differentiation	^€	^&	^§	0.132
High	7	3	0
Moderate	43	15	3
Low	20	5	6
Number of sampled lymph nodes	6 (5–8)	8 (6–10)	8 (4–12)	0.375
Number of positive lymph nodes	1 (1–2)	3 (2–5)	3 (1–5)	0.043

PHCC: perihilar cholangiocarcinoma, GBC: gallbladder carcinoma, IHCC: intrahepatic cholangiocarcinoma.

1 missing data, ^§2 missing data, ^€3 missing data, ^Ω4 missing data, ^ψ7 missing data, ^#8 missing data, *12 missing data.

In patients surviving more than 90 days after operation, histopathological analysis showed cancer-negative margins (>1 mm) in 19 patients only (17%), with no difference between groups (p = 0.606). By defining R0 as cancer-free margins (>0 mm), the number of patients with radical resection was 62 (66%) without difference between groups (p = 0.423).

Recurrence and survival

The median overall survival including all patients was 27 (19–56) months, 18 (13–23) months, and 21 (2–40) months for patients with PHCC, GBC, and ICC, respectively (p = 0.326), as shown in Fig. 1. The median overall survival for patients surviving >90 days post-operatively was 29 (23–34) months, 22 (16–28) months, and 21 (3–40) months for patients with PHCC, GBC, and ICC, respectively (p = 0.530), with an estimated 5-year survival rate of 32%, 20%, and 18% (Fig. 2A). Median recurrence-free survival differed significantly between subtypes (p = 0.046) where IHCC tended to recur earlier than GBC and PHCC (6 (1–10), 15 (8–21), and 18 (1–25) months, respectively) (Fig. 2B).

Fig. 1.

Overall survival in months for all resected patients.

Fig. 2.

(A) Overall survival in months for patients surviving >90 days after operation and (B) recurrence-free survival in months for patients surviving >90 days after operation.

Among patients surviving >90 days post-operatively, multivariable analysis showed that tumor type did not significantly impact survival. As shown in Table 4, factors with a negative impact on survival included low preoperative albumin, lymph node positivity, peritoneal invasion, and postoperative liver failure.

Table 4.

Factors influencing survival (among survivors > 90 days).

Univariable analysis				Multivariable analysis
	HR	95%CI	P	HR	95%CI	P
Age > 70 years	1.49	[0.88, 2.53]	0.136
Female gender	0.79	[0.49, 1.29]	0.353
Body mass index > 25 kg/m²	0.99	[0.54, 1.49]	0.681
Preoperative albumin < 35 g/l	1.53	[0.92, 3.53]	0.100	1.70	[1.01, 2.87]	0.048
Preoperative bilirubin > 30 µ mol/l	1.56	[0.77, 3.16]	0.220
Preoperative biliary decompression	0.72	[0.41, 1.26]	0.253
Portal vein embolization	0.94	[0.56, 1.57]	0.805
Future liver remnant < 30%	1.20	[0.67, 2.17]	0.540
ASA 3	0.91	[0.51, 1.63]	0.751
Perihilar cholangiocarcinoma	Ref
Gallbladder cancer	1.16	[0.60, 2.45]	0.659
Intrahepatic cholangiocarcinoma	1.49	[0.73, 3.05]	0.276
Tumor differentiation
Moderate	Ref
High	0.57	[0.20, 1.59]	0.281
Low	1.06	[0.62, 1.69]	0.833
Tumor stage 3–4	1.41	[0.86, 2.31]	0.170
Resection margin > 0 mm	0.68	[0.42, 1.13]	0.140
Resection margin > 1 mm	0.41	[0.19, 0.91]	0.028	0.48	[0.21, 1.09]	0.078
Lymph node positivity	1.63	[0.99, 2.70]	0.056	2.24	[1.30, 3.86]	0.004
Peritoneal invasion	2.16	[1.32, 3.54]	0.002	1.92	[1.16, 3.17]	0.011
Lymphovascular invasion	2.02	[0.81, 5.04]	0.133
Major postoperative morbidity	1.46	[0.90, 3.56]	0.127	1.49	[0.72, 3.11]	0.285
Postoperative liver failure	1.90	[1.08, 3.34]	0.027	2.13	[1.15, 3.94]	0.016

HR: hazard ratio; CI: confidence interval; ASA: American Society of Anesthesiologists.

Discussion

This single-center study compares tumor characteristics and outcomes of the anatomical subtypes of biliary tract cancer with hilar engagement after major liver resection with extrahepatic bile duct resection. Previous studies comparing biliary tract cancer have shown significant differences in postoperative morbidity and mortality that are often attributed to the anatomical location of the subtypes, rather than tumor biology, requiring surgical resection of different extents.^4,8,9 Our study analyzed patients undergoing extensive surgical resection techniques for all biliary tract cancer subtypes involving the hepatic hilum and confirmed earlier results, showing no significant difference in median overall survival between subtypes (p = 0.52). Our data on GBC with hilar invasion has an overall survival comparable to that of resected GBC as reported in previous studies.¹³ This is in line with a scarce number of publications that have investigated biliary tract cancer with hilar invasion, showing a slightly lower median and 5-year overall survival in GBC, and comparable results for IHCC.^{3,4,10,11,14–16}

Noteworthy, concerning recurrence-free survival, our data revealed significant variation between biliary tract cancer subtypes, showing unusually early recurrence for IHCC, as compared to GBC and PHCC (6, 15, and 18 months, respectively). This is of interest as no study has previously compared recurrence-free survival between all subtypes with hilar invasion. The low recurrence-free survival in IHCC is in line with other western cohorts that recently have shown that about one in four patients with IHCC, regardless of tumor location, experience recurrence within 6 months after surgery.^17,18

Our study showed comparable results to previous studies with an overall 90-day mortality of 13% and major morbidity of 42%.^8,14,19 In this study, GBC patients had a significantly higher postoperative 90-day mortality (29%). The GBC group had a significantly higher number of patients operated with a future liver remnant (FLR) < 30%, although no difference in liver failure was reported between groups. Of note, two GBC patients died within 3 months due to disease dissemination. Contribution reasons for the high perioperative mortality may be the significantly higher frequency of right/extended right hemihepatectomies that was required to achieve negative margins in hilar-invading GBC, a well-known cause of higher morbidity and mortality compared to left or extended left hemihepatectomy.

To our knowledge, no study has previously compared the incidence of peritoneal invasion between biliary tract cancer subtypes nor studied the presence of peritoneal invasion in PHCC. This is a point of interest as perforation of the visceral peritoneum is known to be an adverse prognostic factor in IHCC as well as GBC and is associated with a higher incidence of lymph node metastasis and recurrence.^20,21 In our case, the presence of peritoneal invasion in PHCC was 33%. Results from our multivariable analysis showed that peritoneal invasion is an independent factor (p = 0.011) impacting negatively on survival. This finding may support routine reporting of peritoneal invasion-status in resected cholangiocarcinoma, with benefit from an implementation of standardized histopathological reports.

Another finding in our study is the histopathological results regarding IHCC and GBC with hilar involvement. To this date, very limited eastern series have described or compared either hilar IHCC or GBC with PHCC with none looking at all three subtypes together.^3,4,11,15,16 Moreover, few studies have investigated histopathological factors in GBC with hilar invasion influencing survival with only two older reports investigating this entity.^3,11 Our results showed that, after resection, hilar-invading IHCC and GBC had significantly more known adverse histopathological factors like lymph node positivity, higher number of positive nodes, and larger tumor size. This is in line with previous studies comparing IHCC with PHCC^4,8,9,15,22 and can be attributed to a more advanced tumor stage at presentation in IHCC and GBC when involving the hilum as compared to PHCC, which arises primarily within this region. Our multivariable analysis showed that lymph node positivity was also an independent factor predicting overall survival. As opposed to the extended lymphadenectomy used in this study, results from studies using local lymphadenectomy, which does not involve the whole hepatoduodenal ligament and aortocaval/hepatic artery stations may have understaged the tumor, thus underestimating the prognostic impact of lymph node metastases.^23,24

When investigating positive resection margin status, which previously has been shown to be a factor negatively influencing both overall and recurrence-free survival in biliary tract cancer, no significant differences in survival were found in this study, although, by defining a positive margin as a cancer-free margin of >1 mm, we found a close to significant effect (p = 0.078). Our study had an unusually low number of patients with cancer-free margins. This may be attributed to extensive tissue sampling and a higher number of resection margins assessed. Our cohort included the circumferential hepatoduodenal ligament and hilar margins, in contrast to most eastern as well as western studies that reported only radial, proximal, and distal bile duct margins.^25,26 Ambiguity and inconsistency in reporting resection margins has previously been described as a controversial subject in biliary tract cancer due to lack of a standardized method of histopathological assessment, which makes comparisons between studies difficult.²⁷

The main weakness of this study is the relatively small number of patients in each group, making firm conclusions difficult to draw. Major liver resection including resection of extrahepatic bile ducts is standard treatment for localized PHCC. However, few patients with hilar-invading GBC and IHCC are considered for surgery because of advanced disease, introducing a selection bias to our results. With this in mind, conclusively, IHCC and GBC with hilar involvement demonstrated comparable overall survival but worse histopathological characteristics as compared to PHCC. This may be explained by the fact that hilar-invading GBC and IHCC is usually diagnosed at an advanced stage reflecting the difficulty in achieving curative resection despite undergoing the same extent of surgery as PHCC. This may be further supported by our results showing a shorter recurrence-free survival of 6 months in IHCC as compared to GBC (15 months) and PHCC (18 months). Our results may hence question the aggressive surgical approach in hilar-invading IHCC and aid future discussion on which of the biliary tract subgroups with hilar invasion can benefit from surgical resection. Furthermore, the differences displayed in recurrence-free survival in our study motivate further research on complementary and alternative oncological treatments like kinase inhibitors,²⁸ which only recently have shown promising results in IHCC. The elevated 90-day mortality in patients with GBC similarly motivates consideration of alternative approaches in frail or elderly patients, although preoperative optimization of the FLR (that is, volume modulation) maybe was underused in this group. In addition, two patients with GBC died of tumor dissemination within 90 days of operation after curative resection, addressing the need for a meticulous preoperative radiological workup regarding tumor spread.

Footnotes

Author contributions

All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by HAA and CS. The first draft was written by HAA, and all authors commented on the manuscript. All authors read and approved the final manuscript.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was financially supported by Region Stockholm and the Center for Innovative Medicine, Stockholm, Sweden.

ORCID iD

Christian Sturesson

References

Banales

Marin

JJG

Lamarca

, et al: Cholangiocarcinoma 2020: The next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 2020;17:557–588.

Forner

Vidili

Rengo

, et al: Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int 2019;39(suppl. 1):98–107.

Nasu

Tanaka

Hirano

, et al: The prognosis after curative resection of gallbladder cancer with hilar invasion is similar to that of hilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2012;19(3):274–280.

Zhang

Bagante

Chen

, et al: Perioperative and long-term outcome of intrahepatic cholangiocarcinoma involving the hepatic hilus after curative-intent resection: Comparison with peripheral intrahepatic cholangiocarcinoma and hilar cholangiocarcinoma. Surgery 2018;163:1114–1120.

Mizuno

Ebata

Nagino

: Advanced hilar cholangiocarcinoma: An aggressive surgical approach for the treatment of advanced hilar cholangiocarcinoma: Perioperative management, extended procedures, and multidisciplinary approaches. Surg Oncol 2020;33:201–206.

Neuhaus

Thelen

Jonas

, et al: Oncological superiority of hilar en bloc resection for the treatment of hilar cholangiocarcinoma. Ann Surg Oncol 2012;19:1602–1608.

Popescu

Dumitrascu

: Curative-intent surgery for hilar cholangiocarcinoma: Prognostic factors for clinical decision making. Langenbecks Arch Surg 2014;399(6):693–705.

Roos

Strijker

Franken

, et al: Comparison of short- and long-term outcomes between anatomical subtypes of resected biliary tract cancer in a Western high-volume center. HPB 2020;22(3):405–414.

Ercolani

Dazzi

Giovinazzo

, et al: Intrahepatic, peri-hilar and distal cholangiocarcinoma: Three different locations of the same tumor or three different tumors? Eur J Surg Oncol 2015;41:1162–1169.

10.

Endo

Shimada

Fujii

, et al: Indications for curative resection of advanced gallbladder cancer with hepatoduodenal ligament invasion. J Hepatobiliary Pancreat Surg 2001;8(6):505–510.

11.

Shimizu

Kimura

Yoshidome

, et al: Aggressive surgical approach for stage IV gallbladder carcinoma based on Japanese Society of Biliary Surgery classification. J Hepatobiliary Pancreat Surg 2007;14(4):358–365.

12.

D’Souza

Al-Saffar

Fernández Moro

, et al: Redefining resection margins and dissection planes in perihilar cholangiocarcinoma-radical resection is a rare event. Virchows Arch 2022;480:557–564.

13.

Margonis

Gani

Buettner

, et al: Rates and patterns of recurrence after curative intent resection for gallbladder cancer: A multi-institution analysis from the US Extra-hepatic Biliary Malignancy Consortium. HPB 2016;18(11):872–878.

14.

Kuipers

De Savornin Lohman

EAJ

Van Dooren

, et al: Extended resections for advanced gallbladder cancer: Results from a nationwide cohort study. Ann Surg Oncol 2021;28(2):835–843.

15.

Sano

Shimada

Sakamoto

, et al: Prognosis of perihilar cholangiocarcinoma: Hilar bile duct cancer versus intrahepatic cholangiocarcinoma involving the hepatic hilus. Ann Surg Oncol 2008;15:590–599.

16.

Nakagohri

Asano

Kinoshita

, et al: Aggressive surgical resection for hilar-invasive and peripheral intrahepatic cholangiocarcinoma. World J Surg 2003;27:289–293.

17.

Zhang

Beal

Bagante

, et al: Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. Br J Surg 2018;105(7):848–856.

18.

Doussot

Gonen

Wiggers

, et al: Recurrence patterns and disease-free survival after resection of intrahepatic cholangiocarcinoma: Preoperative and postoperative prognostic models. J Am Coll Surg 2016;223(3):493.e2–505.e2.

19.

Van Keulen

Franssen

Van der Geest

, et al: Nationwide treatment and outcomes of perihilar cholangiocarcinoma. Liver Int 2021;41(8):1945–1953.

20.

Okada

Kijima

Imaizumi

, et al: Clinical significance of wall invasion pattern of subserosa-invasive gallbladder carcinoma. Oncol Rep 2012;28(5):1531–1536.

21.

Kojima

Umeda

Fuji

, et al: Efficacy of surgical management for recurrent intrahepatic cholangiocarcinoma: A multi-institutional study by the Okayama Study Group of HBP surgery. PLoS One 2020;15(9):e0238392.

22.

Tran Cao

Zhang

Sada

, et al: The role of surgery and adjuvant therapy in lymph node-positive cancers of the gallbladder and intrahepatic bile ducts. Cancer 2018;124:74–83.

23.

Zhang

Chen

Kimbrough

, et al: Lymphadenectomy for intrahepatic cholangiocarcinoma: Has nodal evaluation been increasingly adopted by surgeons over time? A national database analysis. J Gastrointest Surg 2018;22(4):668–675.

24.

, et al: Extended lymphadenectomy versus regional lymphadenectomy in respectable hilar cholangiocarcinoma. J Gastrointest Surg 2020;24(7):1619–1629.

25.

Hosokawa

Shimizu

Yoshitomi

, et al: Outcomes of left trisectionectomy and right hepatectomy for perihilar cholangiocarcinoma. HPB 2019;21(4):489–498.

26.

De Wilde

Groot Koerkamp

: Radial margin status should be determined in resected perihilar cholangiocarcinoma. Hepatobiliary Surg Nutr 2019;8(5):557–559.

27.

Roos

Franken

Soer

, et al: Lost in translation: Confusion on resection and dissection planes hampers the interpretation of pathology reports for perihilar cholangiocarcinoma. Virchows Arch 2019;475:435–443.

28.

Goyal

Meric-Bernstam

Hollebecque

, et al; FOENIX-CCA2 Study Investigators: Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med 2023;388(3):228–239.

Different biliary tract cancers,same operation: Importance of cancer origin in patients with hilar-invading tumors

Abstract

Background and Aims:

Methods:

Results:

Conclusion:

Keywords

Context and Relevance

Introduction

Methods

Patient selection and variables

Statistical analysis

Ethical approval

Results

Patient characteristics

Perioperative data

Pathology characteristics

Recurrence and survival

Discussion

Footnotes

Author contributions

Declaration of conflicting interests

Funding

ORCID iD

References